



ASX: HWH RELEASE

October 29, 2021

INVESTOR WEBINAR PRESENTATION

Sydney: Predictive analytics and Artificial Intelligence company Houston We Have (the Company) (ASX:HWH) is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 29th of October 2021 from 12:30pm AEDT / 9:30am AWST.

Executive Chairman Andrew Grover will provide an overview of the Company's recently acquired business ECHOiQ – a company aiming to reinvent cardiac diagnostics using advanced AI. Andrew will share details of recently announced clinical studies and strategic partnerships. A Q&A session will follow the presentation.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/5416151767246/WN_yeWO-ozdRLqftCfMh9bwtA

A recorded copy of the webinar will be made available following the event.

A copy of the investor presentation to be delivered during the webinar is attached.

-ENDS-

Authorised for release by the Board of Directors of Houston We Have Ltd

Media enquiries:

Media & Capital Partners

Kristian Towse / Kris.Towse@mcpartners.com.au

Investor enquiries:

Andrew Grover, Executive Chair / Andrew.grover@echoiq.ai / +61 (0) 481 339 512
investor@HoustonWeHave.ai

ABOUT

Houston We Have (ASX: HWH) is a technology forward company that uses patented augmented intelligence software, data science and commercial insight to help organizations make better decisions, at speed and without bias. ECHO IQ is a wholly-owned subsidiary of Houston We Have, headquartered in Sydney, Australia. More information is available at www.houstonwehave.ai

ECHOiQ

.....

Using the power of artificial intelligence to
reinvent cardiac diagnostics

Disclaimer & Forward Looking Statements

This presentation has been prepared by Houston We Have “HWH”. This document contains background information about HWH current at the date of this presentation, 6 September 2021. The presentation is in summary form and does not purport to be all inclusive or complete. Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinions contained in this presentation.

This presentation is for information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sales of shares in any jurisdiction.

This presentation does not constitute investment advice and has been prepared without taking into account the recipient’s investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons. Recipients should seek professional advice when deciding if an investment is appropriate. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

To the fullest extent permitted by law, HWH its officers, employees, agents and advisors do not make any representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of any information, statements, opinions, estimates, forecasts or other representations contained in this presentation. No responsibility for any errors or omissions from this presentation arising out of negligence or otherwise are accepted.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions which are outside the control of HWH. Actual values, results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward looking statements. Any forward-looking statements in this presentation speak only at the date of issue of this presentation. Subject to any continuing obligations under applicable law, HWH does not undertake any obligation to update or revise any information or any of the forward-looking statements in this presentation or any changes in events, conditions, or circumstances on which any such forward looking statement is based.

ECHOiQ

A company with a singular vision.

To reinvent cardiac diagnostics using the power of AI.

Acquired by ASX-listed **Houston We Have (HWH)** in June 2021

- AI specialists with patented proprietary technology
- Increasingly health focussed

Houston We Have: Corporate Snapshot

Capital Structure (ASX:HWH)

Share price (28 October 2021)	\$0.15
Shares on issue	387,207,713
Options Issued	169,550,900
Market Capitalisation	\$62M
Net Cash Balance	\$3.812M + OPT

* All values in AUD / A\$

Shareholding Concentration

# Shareholders	% Shareholding
Top 10	38%
Top 20	52%

FROM:

Houston
we
Have

TO:

ECHOiQ

Re-branding our parent entity: AGM 29 November, 2021.

Reflective of our strategic focus and the commercial opportunity we see.

ECHOiQ


We are focused on the heart:
Cardiovascular diseases kill 3 in 10
people worldwide.

Developing applications that use
existing clinical infrastructure and
workflows to increase disease risk-
profile detection, and therefore
pathways for treatment.

Echocardiograms are commonly and
widely used. #1 Medicare line item.



Our first solution identifies patients
at-risk of Aortic Stenosis, the most
prevalent form of heart valve disease.



1 Research confirms widespread underdiagnosis

Technology enabled diagnostic capability is increasing faster than traditional diagnostic guidelines

ECHOiQ's mission is to help significantly reduce unnecessary death from undiagnosed heart diseases.

*Baker Heart & Diabetes Institute
“Time to listen to the heart”
(White Paper / August 2021)


2 Unique access to big data linked to mortality

ECHOiQ holds **exclusive** access to the world's largest and most extensive database of its kind with almost **2 million** echos.




3 Real advances in tech capability

Machine learning, neural networks and other AI techniques are now **advanced** enough to deliver a **step-change** in capability



ECHOiQ has 17 years **exclusive** access to NEDA echocardiographic measurement data – the largest of its type (linked to mortality) worldwide.




Solutions Development



Machine Learning & AI applied to big data from NEDA



Cutting edge research in cardiac diagnostics



Algorithm for an AT-RISK profile of key diseases

ECHOiQ ESP – ENHANCED SCREENING PROGRAM

MORE USABLE DATA
+50%



GUIDELINE DETECTION
100%





RISK DETECTION
+100%



Clinical Study

PHASE

- 1** ECHOiQ Algorithm POC **developed** using machine learning, data science and imputation 
- 2** Algorithm **validation** study on 330,000 records successfully completed and published 
- 3** **Clinical validation in the form of a retrospective observation and evaluation study**
- 4** Commercial readiness and go to market

Partners:
NEDA + Edwards LifeSciences + St.Vincent's Sydney

Funding:
Study fully funded by Edwards LifeSciences
(Global valve sales >US\$3.6bn per year / Mkt Cap US\$75B)

Timing:
Site 1 commence Nov 2021
Site 2 commence Dec 2021
Conclusion Q1 2022



RETROSPECTIVE REVIEW

- Earliest opportunity
- Clinical Study > Review
- Identify **additional** patients
- Invite back for review
- Hospitals and labs



REPORTING WORKFLOW INTEGRATION

- Extential partnership
- Serves up an assessment
- ECHOiQ “Button”
- Risk-Indicator signal
- Decision rests with Dr



HARWARE INTEGRATION

- Real-time guidance
- Sonographer’s aid
- Additional measurements
- Improving measurement quality

ECHOiQ

Using the power of ai to reinvent
cardiac diagnostics

Investor enquiries:

Andrew Grover, Executive Chair / Andrew.grover@echoiq.ai
investor@HoustonWeHave.ai

Media enquiries:

Media & Capital Partners
Kristian Towse / Kris.Towse@mcpartners.com.au